Abstract: A non-viral delivery complex comprising a cationic core which is a nanoparticle comprising a peptide having a polycationic nucleic acid binding component, a cleavable spacer element and a cell surface receptor binding component; a nucleic acid and optionally a cationic lipid; and an anionic liposomal coating surrounding the cationic core, said coating comprising lipids from a subject's cells. Also related formulations, uses and methods.

Abstract: A nerve interface device including at least one cuff portion having an assembled position in which the cuff portion forms at least part of a passageway for receiving a nerve along a longitudinal axis passing through the passageway; and first and second rings of electrodes mounted on the at least one cuff portion, each ring of electrodes including a plurality of electrodes. Each electrode in the first ring has a corresponding longitudinally-aligned electrode in the second ring so as to form a plurality of pairs of electrodes spaced apart from each other along the longitudinal axis. The plurality of pairs of electrodes includes at least a first pair of electrodes, the first pair of electrodes mounted on the at least one cuff portion. The at least one cuff portion includes an asymmetric configuration about a central axis perpendicular to the longitudinal cuff axis.

Abstract: There is provided a nerve activity monitoring method that includes receiving an input signal indicative of activity in a nerve of a subject; receiving physiological data indicative of physiological activity in the subject; establishing a relationship between the physiological data and the input signal; identifying a plurality of periodic portions in the input signal based on the relationship between the physiological data and the input signal; and outputting the periodic portions identified.

Abstract: A process for producing a solid pharmaceutical dosage formulation, said process comprising powder bed fusion selective laser 3-dimensional printing of a mixture comprising: (a)a drug; and (b)an excipient; whereinat least one of said drug and said excipient absorbs electromagnetic radiation at a wavelength emitted by the laser; or (a)a drug; (b)an excipient; and (c)an absorbent material which absorbs electromagnetic radiation at a wavelength emitted by the laser.

Abstract: The present invention generally relates to the field of dietary therapies for treating disorders associated with mitochondrial dysfunction, including epilepsy.

Abstract: Bioprosthetic heart valves and methods for fabricating bioprosthetic heart valves are provided. Biological tissue is attached to biocompatible material. The biocompatible material is folded to form a tubular structure with the attached biological tissue located on the inner surface of the tubular structure, the biological tissue forming leaflets of the heart valve. A stent is secured around the outer surface of the tubular structure. A region of the biocompatible material is cut. The biocompatible material is folded at the cut region away from the tissue and around the downstream edge of the stent and is secured to the stent's outer surface. The biocompatible material is folded at the upstream end of the tubular structure around the upstream edge of the stent and attached to the stent's outer surface so that the stent's inner and outer surfaces are covered with no more than a single layer of the biocompatible material.

Abstract: The present invention relates generally to methods and materials for use in photothermal or sonodynamic therapy. The invention novel nanoparticles for use in delivering sensitizers to solid tumour target, wherein the nanoparticles are composed of a polymers or co-polymer of monomers linked by peptide bonds, wherein the polymer or co-polymer comprises one or both of glutamate or derivatised glutatamic acid, and optionally a further, different, monomer which is a naturally occurring amino acid or synthetic monomer having a side chain group, wherein the polymer or co-polymer is not composed only of glutamate. The pendant groups and/or side chains of the polymer or co-polymer interact non-covalently with the sensitizer.

Abstract: There is described a gene therapy approach for treating Wilson's disease in which a nucleic acid molecule is used which comprises a nucleotide sequence encoding for a functional ATP7B protein wherein the nucleotide sequence has at least 85% identity to the sequence of SEQ ID NO. 1. Also described are vectors comprising the nucleotide sequence and methods and uses thereof.

Abstract: A method and apparatus are provided for measuring a sensitivity level across a visual field of a subject defined by a set of locations.

Abstract: Disclosed is a method and apparatus for determining a concentration of a glycopeptide antibiotic containing a phenol moiety such as Vancomycin in a complex sample matrix by extracting the glycopeptide antibiotic from a metered portion of the complex sample matrix by exposing said metered portion to an extraction material having an affinity with the glycopeptide antibiotic; and exposing the extraction material to a metered portion of an eluent for releasing the glycopeptide antibiotic from the extraction material; and by determining a concentration of the glycopeptide antibiotic by adding a Gibbs reagent (2,6 dichloroquinone-4-chloroimide) to the metered portion of the complex sample matrix or the eluent; activating the Gibbs reagent and, after the reaction between the activated Gibbs reagent and the antibiotic has stabilized; detecting the reaction product of the activated Gibbs reagent and the antibiotic in said eluent; and determining the concentration of the antibiotic in the complex sample matrix from the

Abstract: The present invention relates to conjugates of cyclosporin with quinolium mitochondrial targeting groups, and their therapeutic uses.

Abstract: This invention relates to memory resistors, arrays of memory resistors and a method of making memory resistors. In particular, this invention relates to memory resistors having an on state and an off state, comprising: (a) a first electrode; (b) a second electrode; (c) a dielectric layer disposed between the first and second electrodes; wherein the dielectric layer comprises nanoparticles of semiconductor material, and wherein in the on state nanoparticles form at least one conductive filament encapsulated by the dielectric layer, thereby providing a conductive pathway between the first electrode and the second electrode.

Abstract: There is described a nucleic acid molecule comprising a nucleotide sequence encoding for a functional preproinsulin protein wherein the nucleotide sequence has at least 86% identity to the sequence of SEQ ID NO. 1. Also described are: vectors comprising the nucleic acid molecule for expressing the preproinsulin protein; host cells comprising the nucleic acid molecule or a vector; a transgenic animal comprising cells comprising the nucleic acid molecule or the vector; a pharmaceutical composition comprising the nucleic acid molecule or the vector; a method of treating diabetes comprising administering a therapeutically effective amount of the vector to a patient suffering from diabetes; the nucleic acid molecule for use in therapy; and the nucleic acid molecule or the vector for use in the treatment of diabetes.

Abstract: A method and apparatus are provided for calibrating a wireless access point comprising an array of multiple (m) antennas denoted Ai (i=1 . . . m), each antenna having a respective internal phase offset ?i. The method comprises receiving a signal from at least one transmitter located at a substantially known bearing from the wireless access point. The method further comprises determining an estimated value for each internal phase offseti such that an angle of arrival (AoA) spectrum calculated for the received signal on the basis of said estimated values matches the known bearing, wherein said AoA spectrum is calculated by treating said multiple antennas as a phased array. A method and an apparatus are also provided for calibrating a wireless access point comprising first and second arrays of multiple antennas, each antenna array having a respective radio unit, and each antenna in an array having a respective internal phase offseti.

Abstract: The invention relates to a new, more potent, coagulation factor IX (FIX) expression cassette for gene therapy of haemophilia B (HB). Disclosed is a vector for expressing factor IX protein, the vector comprising a promoter, a nucleotide sequence encoding for a functional factor IX protein and an intron sequence, wherein the intron sequence is positioned between exon 1 and exon 2 of the nucleotide sequence encoding for a functional factor IX protein, and wherein the intron sequence has at least 80% identity to the sequence of SEQ ID NO. 1 as disclosed herein.

Abstract: Provided herein are antibodies that specifically bind Tau and methods of using the same.

Abstract: Methods for treating a human subject who has X-linked Retinitis Pigmentosa (XLRP) or another clinically-defined ophthalmological condition due to a loss-of-function mutation in the gene encoding the retinitis pigmentosa GTPase regulator (RPGR) protein, the method comprising administering to the subject a nucleic acid comprising an adeno-associated viral vector comprising an abbreviated human RPGR cDNA.

Abstract: The present invention provides a method for producing a solution of nanosheets, comprising the step of contacting an intercalated layered material with a polar aprotic solvent to produce a solution of nanosheets, wherein the intercalated layered material is prepared from a layered material selected from the group consisting of a transition metal dichalcogenide, a transition metal monochalcogenide, a transition metal trichalcogenide, a transition metal oxide, a metal halide, an oxychalcogenide, an oxypnictide, an oxyhalide of a transition metal, a trioxide, a perovskite, a niobate, a ruthenate, a layered III-VI semiconductor, black phosphorous and a V-VI layered compound. The invention also provides a solution of nanosheets and a plated material formed from nanosheets.

Abstract: The present invention relates to a method of detecting a therapeutic cell expressing a dopamine transporter (DAT) at a central nervous system (CNS) site in a subject, which comprises the administration of a DAT tracer to the subject, wherein the presence of a therapeutic cell which expresses the DAT is determined.

Abstract: A method and an apparatus are provided for performing passing sensing using wireless digital communications. The wireless digital communications are frame-based with a predefined frame structure. The method includes receiving a reference signal into to a reference channel, wherein the reference signal comprises a direct version of a radio frequency transmission as part of said wireless digital communications; receiving a surveillance signal into a surveillance channel; detecting and extracting portions of the reference signal corresponding to data transmissions based on said predefined frame structure; extracting portions of the surveillance signal corresponding to the extracted portions of the reference signal; performing a cross-correlation on the extracted portions of the reference signal and the surveillance signal to determine a range-Doppler surface; and providing a real-time display of said range-Doppler surface and/or of information derived therefrom.